[CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW]

Area of Science:

• Hematology
• Oncology
• Lymphoma Research

Background:

• Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a high relapse rate.
• Current treatment strategies for MCL require careful consideration of patient age and fitness.
• Relapsed MCL presents significant therapeutic challenges.

Purpose of the Study:

• To review and evaluate current treatment approaches for mantle cell lymphoma.
• To outline optimal therapeutic strategies for both newly diagnosed and relapsed MCL.
• To discuss the evolving role of novel biologic agents in MCL management.

Main Methods:

• Literature review of current treatment guidelines and clinical trial data for MCL.
• Analysis of treatment efficacy based on patient demographics (age, fitness status).
• Evaluation of chemotherapy, stem cell transplantation, and targeted biologic therapies.

Main Results:

• For younger patients, high-dose cytarabine chemotherapy followed by autologous stem cell transplantation is standard.
• Older patients often benefit from bendamustine and rituximab, with potential rituximab maintenance.
• For relapsed MCL, chemotherapy (bendamustine, cytarabine) or biologic agents like ibrutinib are options, with ibrutinib showing high response rates.

Conclusions:

• Treatment for MCL must be individualized based on patient characteristics and disease status.
• Novel biologic agents, particularly Bruton tyrosine kinase inhibitors, show promise for future MCL treatment, potentially leading to a 'chemo-free' era.
• Effective management of relapsed MCL remains critical, with targeted therapies offering new hope.